Otto I Pulkkinen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Otto I Pulkkinen

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Frontiers in Pharmacology|October 13, 2022

Target-specific compound selectivity for multi-target drug discovery and repurposingTianduanyi Wang, Otto I Pulkkinen, Tero Aittokallio

Plos Computational Biology|December 28, 2020

Multiobjective optimization identifies cancer-selective combination therapiesOtto I Pulkkinen, Prson Gautam, Ville Mustonen, et al.

Genes and Immunity|May 22, 2024

TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicityMiriam Langguth, Eleftheria Maranou, Saara A Koskela, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Frontiers in Pharmacology|October 13, 2022

Target-specific compound selectivity for multi-target drug discovery and repurposingTianduanyi Wang, Otto I Pulkkinen, Tero Aittokallio

Plos Computational Biology|December 28, 2020

Multiobjective optimization identifies cancer-selective combination therapiesOtto I Pulkkinen, Prson Gautam, Ville Mustonen, et al.

Genes and Immunity|May 22, 2024

TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicityMiriam Langguth, Eleftheria Maranou, Saara A Koskela, et al.

Pageof 1